BioSpace News Archive

Coherus BioSciences, Inc., announced that effective Nov. 5, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 177,500 shares of the common stock of the Company to newly hired employee with a per share exercise price of $17.81, the closing trading price on the grant date.

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the quarter ended September 30, 2021 and highlighted recent corporate progress.

Graphite Bio, Inc. today reported recent business progress and third quarter 2021 financial results.

Generation Bio Co reported recent business highlights and third quarter 2021 financial results.

Vicarious Surgical to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today reported financial results for the three months ended September 30, 2021, its fiscal third quarter, and provided an overview of recent progress and accomplishments.

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that Evan Loh, chief executive officer, will present at the 2021 Jefferies London Healthcare Conference. The on-demand presentation will be available Thursday, Nov. 18 beginning at 3 a.m. EST through Friday, Nov. 19 at 12 p.m. EST.

Tempest Therapeutics, Inc., a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, reported financial results and provided a corporate update for the third quarter ended September 30, 2021.

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2021.